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Background: The use of human acellular dermis (hAD) to close open abdomen in the treatment process of
severe peritonitis might be an alternative to standard care. This paper describes an investigation of the effects
of fluids simulating an open abdomen environment on the biomechanical properties of Epiflex® a cell-free human
dermis transplant.
Methods: hAD was incubated in Ringers solution, blood, urine, upper gastrointestinal (upper GI) secretion and a
peritonitis-like bacterial solution in-vitro for 3 weeks. At day 0, 7, 14 and 21 breaking strength was measured, tensile
strength was calculated and standard fluorescence microscopy was performed.
Results: hAD incubated in all five of the five fluids showed a decrease in mean breaking strength at day 21 when
compared to day 0. However, upper GI secretion was the only incubation fluid that significantly reduced the
mechanical strength of Epiflex after 21days of incubation when compared to incubation in Ringer’s solution.
Conclusion: hAD may be a suitable material for closure of the open abdomen in the absence of upper GI leakage
and pancreatic fistulae.
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Acellular dermal products and transplants are starting
to play a significant role in reconstructive surgery [1-3].
Human acellular dermis (hAD) may offer some advantages
over xenogeneic material, such as reduced immunogen-
icity and increased safety with regard to potential prion
infections [4]. Although the hAD Alloderm® has been
extensively used outside of Europe and in particular in
the USA [5-9], it is not approved for use in Germany
where tissue transplants are required to meet the stringent
safety requirements of the German drug law. Epiflex® is
currently the only hAD approved for use as a medicinal
product in Europe [4].* Correspondence: eric.roessner@umm.de
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distribution, and reproduction in any mediumDermis is rich in collagen of various subtypes [10] and
its biomechanical strength is principally a function of the
density and degree of hydration [11] and crosslinking [12]
of the collagen fibers. These factors will also influence the
extent to which a hAD retains its mechanical strength
when incubated in aggressive fluids akin to those present
in an infected open abdomen.
An open abdomen is defined as an abdominal wall
fascial defect persisting after laparotomy. This condition
may be induced, or accepted in case of a planned second
look, for prevention of abdominal compartment syndrome
or during “damage control surgery”, or it may simply be
impossible to close the abdomen due to loss of domain,
extensive abdominal wall resection or insufficient fascial
stability in the case of peritonitis [13]. Due to the success
of commercial and non-commercial vacuum therapy
regimes in open abdomen management, fascial closure
rates of up to 100% in young damage control trauma
patients can be achieved [13,14]. Closure rates in multi-ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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only 30%. In cases where fascial closure fails or vacuum
therapy is not available the abdomen is traditionally
closed with a synthetic mesh [15]. Since the abdominal
compartment is usually contaminated in such patients,
a resorbable mesh (e.g. Vicryl) is used. These meshes
resorb in the time taken for the abdominal defect to be
filled by granulation tissue and a planned ventral hernia
is developing. This hernia will then be repaired after 6–
12 months, when secondary wound healing finished and
an aseptic condition is achieved, with non-resorbable,
synthetic meshes and/or component separation techniques
[16]. Application of a biological mesh such as hAD in the
initial phase could be a novel approach in such patients.
To function in this setting, a hAD must be sufficiently
structurally resistant to the hostile environment of an open
abdomen containing blood, urine or stool from fistulas
and typical bacteria found in peritonitis patients. If such a
treatment regime could obviate planned ventral hernias,
this could reduce morbidity, and the requirement for
revisions. Manufactures of these biological meshes are
heavily advertising these for the closure of a septic
open abdomen, claiming their biostability without a
proper proof. The intention was the proof of principle
and to identify conditions not suitable for a repair with
acellular dermis.
The present study focuses on an in-vitro examination of
the effect of incubation in Ringer’s solution (physiological
solution serving as a control group), urine, blood, a
bacteria mixture and upper gastrointestinal (upper GI)
secretion on the mechanical strength of hAD.
Methods
All of our research was carried out in compliance to the
Helsinki declaration. The blood donation was approved
by the local ethics committee ( Ethic Approval 87/04
of the Ethik Kommission II der Medizinischen Fakultät
Mannheim).
Human acellular dermis
Epiflex® (German Institute for Cell and Tissue Replacement,
Berlin, Germany) was used as hAD. The transplant mater-
ial used in the study originated from five screened and
consenting human cadaveric donors. The mechanical
processing, decellularization, sterilization and preservation
methods [4] and collagen content [10] are described in
detail elsewhere. All samples were derived from same
body region. Each donor was randomized into one of
the five groups (control, blood, urine, upper GI secretion
and bacterial solution).
Incubation fluids and culture conditions
The hAD were incubated in Ringer’s solution, in 1 of 3
different human body fluids; whole blood, duodenalsecretion, urine or in a bacteria mixture consisting of en-
terococcus faecalis (gram+; streptococci), staphylococcus
aureus (gram+; staphylococci), e.coli (gram-; enterobacte-
riaceae) and pseudomonas aeruginosa (gram-; nonfermen-
ter). The bacterial strains were provided by the Institute
for Medical Microbiology and Hygiene, (University
Medical Center Mannheim) and added at a concentration
of 1x105ml-1 in Dulbecco’s Modified Eagle Medium
(DMEM) with high glucose (4.5 g/l) and no additives
(PAA, Germany), aliquoted and frozen at −80°C
(mixed 1:1 with glycerol) for later use. Upper gastro
intestinal secretion was collected from consenting pa-
tients during upper gastrointestinal endoscopy procedures.
In all cases it was necessary to evacuate the upper GI in
order to examine the intestinal mucosa. Upper GI path-
ology could be ruled out in all patients and none had
been taking anti-acid medication. The secretions were
pooled into volumes of 5 litres, aliquoted into 15 ml tubes
and stored at −80°C. Urine was collected daily from
healthy voluntary donors.
Blood was retrieved from the Institute of Transfusion
Medicine and Immunology, German Red Cross Blood
Service. Centrifugation of whole blood separates the sam-
ples into erythrocyte concentrate, plasma and a thrombo-
cyte and leucocyte rich buffy coat. The latter are further
used to create pooled thrombocyte concentrates. Due to
use of mainly - antihypertensive - medication, the buffy
coats and plasma were not permitted for use in patients.
To simulate cellular blood composition, especially of
leucocytes that are mainly regarded responsible for diges-
tion of foreign bodies, the blood used in these experiments
was composed of both buffy coat and plasma of volunteer
blood donors.
Culture conditions
The transplant samples were rehydrated in Ringer´s
solution for 30 minutes at room temperature and then
incubated at 37°C in 10 ml of one of the test fluids.
The test fluid completely covered the hAD sample.
Nine samples were incubated in each of the fluids.
The incubation fluids were replaced on a daily basis.
With the exception of the bacteria mixture, the dishes
were supplemented with a 1:100 dilution of a Penicillin/
Streptomycin mixture (PAA, Germany) to give a final
concentration of 100 U/ml Penicillin and 0,1 mg/ml
Strepavidin. Samples were incubated for 0 (briefly
rinsed), 7, 14 and 21 days.
Measurement of mechanical properties
Samples for mechanical testing were punched out of the
transplants with a die cutter (Figure 1). The cut samples
were submersed in Ringer´s solution for about 30 minutes
prior to testing. The thickness of the mechanical test sam-
ples was measured at 5 points using a digital micrometer
Figure 1 Dimensions of mechanical test specimens (ISO compliant).
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The samples were evaluated in a tensile testing apparatus
(H10KM, Richard Hess MBV GmbH, Sonsbeck, Germany)
for ultimate load-at-failure according to EN ISO 527
(Figure 2). The test was carried out with a 100 N load
cell at a constant strain rate of 50 mm/min.
Histology
At the end of the respective incubation period, trans-
plant samples were fixed in 10% formalin for 24 hours,
sliced into 3 equal parts, embedded in paraffin and
sectioned (7 μm) with a microtome (Microm, Germany)
for a complete edge-to-edge cross- sectional view. Samples
were mounted onto glass slides, dried overnight at 37°C,
de- paraffinized with 3 washes of 5 minutes in a xylene
bath followed by 3 washes of 2 minutes each through a
dilution series of 100%, 96% and 80% ethanol. The autoflu-
orescence of the samples was observed with a 488 nm exci-
tation filter and a 514 nm emission filter in a fluorescence
microscope (Zeiss, Germany) and stitched with ICE (Image
Composite Editor, V1.4.4, Microsoft, USA).Figure 2 Sample clamped in the tensile testing machine.Statistics
For data collection and handling Excel 2010 was used
(Microsoft, Redmond). Data was analyzed for normal
distribution. A two-sided multiple Wilcoxon rank test with
a correction according to Bonferroni- Holm for multiple
testing was used. Tests were considered significant when
α ≤ 0.05. For all statistics SAS (SAS Institute Inc., Carry, NC,
USA) and StatXact 9 (Statcon, Witzenhausen, Germany)
software was used. For the Koziol test the statistic system
ADAM version 2.54 (DKFZ, Heidelberg, Germany) was
used. Statistical analyses were conducted by a statistician
of the Medical Faculty Mannheim, Heidelberg University,
Germany.
Results
Results are show in Figure 3. The breaking strength of
hAD in Ringer’s Solution decreases over time. At day 21
the hAD has lost approximately 30% of its breaking
strength. Although there is a continuous decrease of the
mean breaking strength the differences between day 0
(35.28 ± 3.12 N/mm2) and day 7 (34.19 ± 3.50 N/mm2)
and between day 14 (29.32 ± 2.67 N/mm2) and day 21
(24.69 ± 3.27 N/mm2) were not significant. In blood the
breaking strength declines as well over time about 32%,
although only the comparison between day 0 (34.14 ±
5.46 N/mm2) and 21 (23.38 ± 2.97 N/mm2) and between
day 7 (30.0 ± 3.3 N/mm2) and day 21 were significant. A
40% decrease in breaking strength was measured for
hAD incubated in urine for 21 days. The decrease was
not significant between day 0 (34.3 ± 4.48 N/mm2) and
day 7 (32.2 ± 4.215 N/mm2) and between day 7 and day
14 (27.29 ± 3.49 N/mm2). Incubation in a bacterial solution
decreased the hAD breaking strength by 51% over a period
of 21 days. Although the decrease from day 0 (32.42 ±
1.99 N/mm2) to 21 (16.06 ± 6.87 N/mm2) was significant
the intervals from day 0 to 7 (29.01 ± 4.77 N/mm2), from
day 7 to 14 (21.33 ± 2.54 N/mm2) and from day 14 to 21
were not significant. Breaking strength of hAD incubated
in upper GI secretion showed the most distinct decrease
of 78% over 21 days. All intervals showed a significant
decrease in breaking strength. Mean breaking strength
at day 0 was 33.42 ± 4.79 N/mm2, at day7: 25.19 ± 2.94 N/
mm2, at day 14: 12.14 ± 2.045 N/mm2 and at day 21:
7.157 ± 2.84 N/mm2 (Table 1).
Comparing the breaking strengths of hAD in the differ-
ent mediums at day 0 there were no significant differences.
At day 7 the only significantly different treatment incuba-
tion in upper GI secretion. At day 14 both incubation in
upper GI secretion and incubation in the bacteria solution
resulted in mechanical strength being lower at the same
time point than in the other 3 treatment groups. At this
time point, hAD incubated in upper GI was significantly
weaker than that incubated in the bacteria solution. At
day 21 material incubated in upper GI secretion was again
Figure 3 Breaking strength of hAD. The values are indicated as mean ± SEM.
Vitacolonna et al. BMC Surgery 2014, 14:7 Page 4 of 7
http://www.biomedcentral.com/1471-2482/14/7mechanically weaker than that in all other treatments.
However, there were no longer any significantly differ-
ences amongst the samples incubated in Ringer’s solution,
blood, urine and bacteria solution (Table 2).
In the non-parametric analysis of the curves over time
according to Koziol et al. the curve of the hAD incubated
upper GI secretion is significantly (p = 0.0001) lower than
the other curves.
The microscopy analysis of the hAD specimens showed
disaggregation of the collagen fibers in all groups over
time. In the bacterial and upper GI secretion group, disag-
gregation seems to occur more rapidly and more distinct
when compared over time (Figure 4).
Discussion
Since open abdomen is a therapeutic option in the treat-
ment of traumatized abdomen or severe peritonitis there is
a need for minimizing sequelae [17]. The well-established
method of closure with a synthetic resorbable mesh pre-
vents evisceration and chronic foreign body infection,
although complication such as massive adhesions andTable 1 Comparison of measured strength between
paired time points within treatment groups ((+)









Ringer’s solution - + - +
Blood - - - +
Urine - - + +
Bacteria - - - +
Upper GI secretion + + + +small bowel fistulae are well known [18,19]. The need
for major surgery to reconstruct the abdominal wall and
for programmed ventral hernia raises the possibility of
further morbidity, increased costs and mortality [20].
With introduction of intra-abdominal negative pressure
dressings, delayed primary closure became an option in a
high percentage of young trauma patients [21]. Delayed
primary closure might be the best option in such patients,
but in a majority of older patients with severe peritonitis
due to septic focuses this is not feasible [22]. Closure
with a tissue transplant could be helpful if adequate
mechanical stability could be retained in an open abdo-
men environment.
Hollinsky and co-workers [23] measured the tensile
strength of healthy human abdominal wall using specimens
excised from fresh cadaver tissue. They were able to show
that the linea alba fails in longitudinal and transversal
direction at 39 N. This was calculated to be equivalent
to a tensile strength of 10 N/mm2 and this may be
regarded as the maximum strength required in a healthy
human under extreme loads. The mean tensile strength of
the transplants in the control group was 35 N/mm2 at day
0. Even 25 N/mm2, which was the mean strength after 21Table 2 Comparison of measured strength at individual
time points between treatment groups ((+) significant
difference) ((−) no significant difference)
Day 0 Day 7 Day 14 Day 21
Ringer’s solution vs. blood - - - -
Ringer’s solution vs. urine - - - -
Ringer’s solution vs. bacteria - - + -
Ringer’s solution vs. GI secretion - + + +
Figure 4 Representatice fluorescence photomicrographs of hAD specimens incubated in (A) Ringer´s solution at day 21 and (B) in
bacteria mix (collagen autofluorescence excitation 488 nm, emission 514 nm). The figure shows a qualitative comparison of the matrix
disaggregation incubated in control solution and bacteria mix. It can be seen, that matrix disaggregation in the bacteria group was more
pronounced than in Ringer´s solution, presumably due to enzymatic cleavage (e.g. collagenases). Scale bars equal 50 μm.
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able to withstand the maximum anticipated force, more so
since the in-vitro test disregards adhesion and integration
phenomena.
The breaking strength of hAD samples incubated in
blood was not significantly different to that of transplants
incubated in Ringer’s solution. Epiflex® should therefore
be strong enough to reconstruct ventral hernias in an
uninfected situation.
Epiflex® incubated in urine had similar properties. It
should therefore be suitable for ventral reconstruction in
the presence of an urinoma or urinary tract leakage.
Incubation in a bacteria solution resulted in no signifi-
cant loss of strength at day 0 and 7 when compared to
incubation in Ringer’s solution, but there was a significant
difference at day 14. At day 21 there was no longer a sig-
nificant difference. Typical intestinal flora may be capable
of reducing the mechanical strength of Epiflex® within the
time frame under investigation to a greater extent than
blood or urine, although the residual mechanical strength
of 16 N/mm2 still exceeds the calculated requirement.
The study has limitations with regard to the composition
of the bacteria solution. Although the solution represents a
common mixture of bacteria found in peritonitic patients,
different bacteria mixtures could well have significantly
different effects on hAD, since different bacteria strains
and species excrete different concentrations of active
agents such as collagenase.
The samples were incubated in high concentrations of
bacteria that would only arise in an uncontrolled septic
focus in the open abdomen. In such cases, an attempt at
a primary closure would not normally be indicated. The
combined effect of bacterial secretions and the inflamma-
tory host response on the mechanical strength of candidate
materials for abdominal wall closure cannot be simulated
in-vitro.
Upper GI tract secretion had a powerful effect on the
mechanical strength of Epiflex®. Loss of mechanical strength
was continuous and when compared to the effects of theother incubation fluids, significantly increased at day 7, 14
and 21. The presence of an upper GI leakage, the closure
of an open abdomen with Epiflex® might be compromised.
At this stage of an open abdomen therapy, a definite
closure is rarely indicated. It is unclear whether a pure
pancreatic secretion from a pancreas fistula would have
the same impact on the mechanical strength of Epiflex®.
The decrease in mechanical strength in the different
liquids might be caused by various factors. Upper GI se-
cretion is a mixture of gastric fluid, bile and pancreatic
fluid and contains a heterogeneous mixture of digestive
enzymes including proteases, lipases and amylases [24,25].
The upper GI secretion was frozen shortly after collection
at −80°C to retard reduction of enzyme activity. Since
the extracellular matrix consists of various proteins, glyco-
proteins and polysaccharides, enzymatic hydrolysis would
seem to be a likely contributor to loss of tensile strength
[26,27]. Bacteria also secrete hydrolytic enzymes such
as collagenases, whereby the extent and the composition
depends on species and strain. Furthermore, microbial
organisms can modify the pH of the environment [28-30].
This may influence the degradation of bioresorbable mate-
rials [31-33]. It is known that superoxide ions from leuko-
cytes and macrophages accelerate the degradation of
absorbable materials [34]. The mechanism leading to loss
of mechanical strength in Ringer's solution after 21 days is
unclear. Temperature may affect biodegradation [35,36],
however the incubation temperature in our study (37°C)
seems unlikely to have exacerbated hydrolysis. Numerous
studies demonstrated a significant loss in strength of bio-
degradable materials in aqueous solutions, presumably by
cumulative low-level irreversible hydrolysis [33,36,37].
Limitations of the studyy
In the clinical situation wound healing processes such
adhesions to the transplant and integration, remodeling,
vascularization, inflammation and scaring will have an
effect on the mechanical strength of the transplant and
the forming abdominal wall. This limits our findings
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effects are likely to be positive, although it cannot be
ruled out that the remodeling process in itself results
periods during healing during which mechanical strength
is reduced, if resorption processes advance more rapidly
than synthetic processes. The uniaxial tensile stresses
applied to the transplants in our study do not ideally
represent the stresses that occur in vivo. The latter are
dynamic and multidirectional and can best be analyzed
in a clinical setting.
Conclusion
Epiflex® exhibits reduced mechanical strength after 3 weeks
of incubation in Ringer’s solution, in body fluids (blood,
urine, upper GI secretion) and in a bacteria solution. It
seems unlikely that the loss of mechanical strength arising
from incubation in Ringer’s solution, blood and urine
would be clinically significant in the setting of a primary
closure of an open abdomen. The loss of mechanical
strength arising from incubation in a bacteria solution
suggests that this might be clinically significant in an
infected open abdomen situation, depending on the
concentration, species and strain of the contaminating
organisms. Incubation of Epiflex® in upper GI secretion
caused a more pronounced loss of mechanical strength.
Use of hAD for open abdomen closure in the presence
of upper GI leakage or of a pancreatic fistula may be
inappropriate. The authors intend to proceed with a
phase I clinical study. The superiority of hAD in regards
to the development of ventral hernia must be shown in a
phase III study.
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